Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001688327Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE INFORMATIONSubmission Contact InformationIs the second second

Name Phone E-Mail Address

144: Issuer Information

Name of Issuer SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Affiliate

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | | Approximate Date of Sale | Name the Securities Exchange |
|------------------------------------------------|---------------------------------------------------------------------|-----------------------------------------------------|------------------------------|-----------|-----------------------------|------------------------------------|
| Common | BTIG, LLC 350 Bush St. 9th floor San Francisco CA 94104 | 67400 | 707700.00 | 107144465 | 09/13/2024 | NASD |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you

Nature of

Name of

Is Date

Amount of

Nature of

Date of

| Tango Therapeutics, Inc. |
|------------------------------|
| 001-39485 |
| 201 BROOKLINE AVENUE |
| SUITE 901 |
| BOSTON |
| MASSACHUSETTS |
| 02215 |
| (857) 320-4900 |
| Third Rock Ventures IV, L.P. |

| Class | Acquired | Acquisition Transaction | Person from Whom Acquired | Acquired | | Payment | Payment * |
|--------|----------------|----------------------------|---------------------------------|----------|-------|---------------|-----------|
| Common | 03/23/2017 Pro | e-IPO | Purchased from TRV III | | 67400 | 03/23/2017 Wi | re |

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

| Name and Address of Seller | Title of Securities Sold | Date of Sale | Amount of Securities Sold | Gross Proceeds |
|------------------------------------------------------------------------------------|--------------------------|-----------------|---------------------------------|----------------|
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/17/2024 | 550171 | 5386339.14 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/18/2024 | 191490 | 1878478.60 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/22/2024 | 262740 | 2570096.41 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/23/2024 | 125000 | 1223350.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/24/2024 | 200000 | 1963160.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/25/2024 | 100599 | 992771.29 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/26/2024 | 50000 | 491950.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/30/2024 | 95000 | 931114.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 07/31/2024 | 100000 | 993380.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave, Suite 1401 Boston MA 02215 | Common | 08/01/2024 | 40000 | 392000.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave | Common | 08/16/2024 | 135000 | 1321447.50 |

| Suite 1401 Boston MA 02215 | | | |
|-------------------------------------------------------------------------------------|--------|-------------------|------------|
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 08/19/2024 150000 | 1513920.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 08/27/2024 25000 | 288665.00 |
| Third Rock Ventures IV, L.P. 201 Brookline Ave Suite 1401 Boston MA 02215 | Common | 08/30/2024 175000 | 2029702.50 |
| Third Rock Ventures IV, L.P. 350 Bush St. 9th floor San Francisco CA 94104 | Common | 09/05/2024 75000 | 867135.00 |

144: Remarks and Signature

Remarks Date of Notice *ATTENTION:*

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date. Signature Kevin Gillis

09/13/2024

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)